Navigation Links
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Date:2/14/2008

PRINCETON, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the first fiscal quarter of 2008 ended December 31, 2007. Pharmasset reported a net loss attributable to common stockholders of $12.2 million, or ($0.57) per share for the first fiscal quarter of 2008, as compared to net income attributable to common stockholders of $3.6 million, or $0.33 per diluted share for the same period in fiscal 2007.

Revenues were $0.5 million during the first fiscal quarter of 2008, which consisted of the amortization of payments received from Roche from the hepatitis C virus (HCV) collaboration agreement that were previously recorded as deferred revenue. Revenues for the same period in fiscal 2007 were $8.1 million, which included a $7.5 million milestone payment received from Roche. Investment income was $0.9 million during the first fiscal quarter of 2008 compared to $0.4 million during the same period in 2007. The $0.5 million increase in the first fiscal quarter of 2008 was due to higher average invested cash balances.

Total costs and expenses for the first fiscal quarter of 2008 were $13.2 million as compared to $4.6 million for the same period in fiscal 2007. The $8.6 million increase in operating expenses for the first fiscal quarter of 2008 was primarily due to a $7.0 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, as well as approximately $1.6 million in drug discovery, compensation, insurance, audit and non-cash stock compensation expenses
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. CEL-SCI Corporation Reports First Quarter Financial Results
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... RICHMOND, Va., April 18, 2011 BB&T Capital Markets ... LLC, d/b/a Dr. Comfort, the leading developer, manufacturer and ... products, in its sale to DJO Global, an international ... health and pain management based in Vista, Calif. Dr. ...
... GAITHERSBURG, Md., April 18, 2011 Sigma-Tau Pharmaceuticals, ... received approval from the U.S. Food and Drug ... in the oncology medicine ONCASPAR® (pegaspargase).  ONCASPAR is ... is a key component in the treatment of ...
Cached Medicine Technology:BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 3Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 4
(Date:12/17/2014)... Alan Mozes HealthDay ... With the holiday party season fast approaching, a new study ... make DUI arrests have fewer drunk drivers on their roads. ... laws more vigilantly are better able to deter inebriated revelers ... "Hardly any new laws are being passed regarding drinking and ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory consulting ... South America, Europe, the Middle East, Asia and Australia, ... 2015 Medical Device Industry Survey. Each year, Emergo conducts ... market trends as well as regulatory and operational concerns ... , Overall prospects for medical device ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Popular ,Out of the Closet, Thrift Store, Non-profit,AHF Pharmacy, ... Make a Difference, Grand Opening Event to Include ... This Saturday, February,2nd at 10:00 a.m., AIDS Healthcare ... Pharmacy, with a grand opening event to include,a ribbon-cutting ...
... enthused about Part D,s success, but critics say problems ... The three-year-old Medicare Part D drug program is seeing ... for the program fall, U.S. health officials announced Thursday. ... lower than originally projections, enrollment continues to rise and ...
... of the novel drug romiplostim (Nplate) show that it ... thrombocytopenic purpura (ITP), a hematologic disorder that can cause ... 3 trial results for the drug, which duplicates the ... General Hospital (MGH) investigator, in the February 2 issue ...
... International Associates, Inc.,administrator for the HealthShares(TM) Indexes, a ... Funds, today announced,that effective at the opening of ... BIM) will replace GYRUS GROUP PLC (GYG LN),in ... Companies that are included in The HealthShares(TM) ...
... in Karmanos Cancer Institute,s Annual Dinner, May 17, ... Karmanos,Cancer Institute will upgrade its nurse paging system, ... according to Nick Karmanos, vice,president of development for ... "As Lead Sponsor for our 26th Annual Dinner ...
... differences between nonprofit, for-profit banks should be explained , , ... tell pregnant patients considering umbilical cord blood banking about ... blood banks, new guidelines state. , The American College ... Opinion in the February issue of Obstetrics & ...
Cached Medicine News:Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 2Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder 2Health News:Ford Motor Company Fund Continues Longtime Support to Cancer Care 2Health News:Docs Should Tell All About Cord Blood Banks 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: